Executive Briefing
Week ending August 16, 2026
1. Headline
32 cross-response inconsistency flags this week—down 7 from last week, but still double the 16 recorded six weeks ago. The immediate risk is uneven safety and regulatory messaging: some answer variants include boxed warnings or contraindications while others omit them. Competitor visibility remains high, led by Wegovy in 45 answer instances.
2. This week at a glance
| Metric | This week | Change |
|---|---|---|
| Distinct questions / responses | 20 / 130 | Questions flat; responses -10 |
| Inconsistency flags | 32 | -7 |
| Top competitors | Wegovy 45; Mounjaro 24; Trulicity 22 | -1; -2; -3 |
| Top themes | Hedging/disclaimers 117 (-5); dosing 65 (-11); pancreatitis 43 (-2) | — |
3. Trajectory
Safety-message consistency has improved versus last week but remains worse than the early baseline. Inconsistency flags rose from 16 on July 12 to 31 on July 19, peaked at 37 on July 26, briefly fell to 34 on August 2, then reached 39 on August 9 before improving to 32 this week. The clear inflection was the late-July increase in monitoring volume and associated inconsistency; the latest decline is encouraging but not yet a sustained recovery.
Competitor visibility in Ozempic answers has risen materially over six weeks despite this week’s modest decline: Wegovy increased from 16 to 45 mentions, Mounjaro from 8 to 24, and Trulicity from 6 to 22. Ozempic is frequently framed through weight loss, switching, and comparative-effectiveness questions.
4. Where the risk actually is
- Dosing/indication question: boxed-warning content appeared in only 1 of 6 variants, and contraindication content in 1 of 6. A patient asking how to start treatment may receive dosing guidance without the key safety boundary.
- Drug-interaction question: one answer mentioned contraindication and pancreatitis while six omitted each. This creates inconsistent clinical context around a question involving insulin and sulfonylureas.
- Pancreatitis management question: six of seven variants omitted the contraindication-related framing. Most advised stopping and urgent evaluation, but inconsistent wording can affect how firmly the warning is communicated.
5. Recommended actions
- Medical Affairs/PV: Create a controlled AI-answer fact set for boxed warning, contraindications, pancreatitis, hypoglycemia, renal monitoring, pregnancy, and missed-dose guidance; target the flagged PI questions.
- Content/SEO: Publish concise, label-aligned FAQs separating Ozempic from Wegovy, compounded semaglutide, and alternatives; address the 21 off-label and 14 biosimilar/generic theme counts.
- Medical/legal review: Audit comparative claims involving Trulicity and Mounjaro, where “stronger,” “best,” or “superior” language appeared 34 times overall.
- Marketing: Rebalance weight-loss-adjacent framing toward approved Ozempic indications; Wegovy remains the leading competitor at 45 mentions.